221 related articles for article (PubMed ID: 29788880)
1. Recent Advances in Nanosuspension Technology for Drug Delivery.
Arora D; Khurana B; Rath G; Nanda S; Goyal AK
Curr Pharm Des; 2018; 24(21):2403-2415. PubMed ID: 29788880
[TBL] [Abstract][Full Text] [Related]
2. Nanosuspension Technology For Poorly Soluble Drugs: Recent Researches, Advances and Patents.
Agarwal V; Bajpai M
Recent Pat Nanotechnol; 2015; 9(3):178-94. PubMed ID: 27009133
[TBL] [Abstract][Full Text] [Related]
3. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
4. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
5. Preparation, characterization and pharmacokinetics of cyadox nanosuspension.
Sattar A; Chen D; Jiang L; Pan Y; Tao Y; Huang L; Liu Z; Xie S; Yuan Z
Sci Rep; 2017 May; 7(1):2289. PubMed ID: 28536446
[TBL] [Abstract][Full Text] [Related]
6. An overview of recent patents on nanosuspension.
Modh N; Mehta D; Parejiya P; Popat A; Barot B
Recent Pat Drug Deliv Formul; 2014; 8(2):144-54. PubMed ID: 24758487
[TBL] [Abstract][Full Text] [Related]
7. Nanosuspension-Based Drug Delivery Systems for Topical Applications.
Aldeeb MME; Wilar G; Suhandi C; Elamin KM; Wathoni N
Int J Nanomedicine; 2024; 19():825-844. PubMed ID: 38293608
[TBL] [Abstract][Full Text] [Related]
8. Nanosuspensions in drug delivery: recent advances, patent scenarios, and commercialization aspects.
Chavhan SS; Petkar KC; Sawant KK
Crit Rev Ther Drug Carrier Syst; 2011; 28(5):447-88. PubMed ID: 22077201
[TBL] [Abstract][Full Text] [Related]
9. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
10. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
[TBL] [Abstract][Full Text] [Related]
11. Nanosuspension: A Formulation Technology for Tackling the Poor Aqueous Solubility and Bioavailability of Poorly Soluble Drugs.
Elsebay MT; Eissa NG; Balata GF; Kamal MA; Elnahas HM
Curr Pharm Des; 2023; 29(29):2297-2312. PubMed ID: 37694786
[TBL] [Abstract][Full Text] [Related]
12. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
[TBL] [Abstract][Full Text] [Related]
13. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
14. Nanosuspension Technology: Recent Patents on Drug Delivery and their Characterizations.
Goel S; Sachdeva M; Agarwal V
Recent Pat Drug Deliv Formul; 2019; 13(2):91-104. PubMed ID: 31203813
[TBL] [Abstract][Full Text] [Related]
15. Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.
Leone F; Cavalli R
Expert Opin Drug Deliv; 2015; 12(10):1607-25. PubMed ID: 25960000
[TBL] [Abstract][Full Text] [Related]
16. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
[TBL] [Abstract][Full Text] [Related]
17. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery.
Lai F; Schlich M; Pireddu R; Corrias F; Fadda AM; Sinico C
Curr Pharm Des; 2015; 21(42):6089-103. PubMed ID: 26503149
[TBL] [Abstract][Full Text] [Related]
18. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
Zawar LR; Bari SB
Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
[TBL] [Abstract][Full Text] [Related]
19. Recent survey on nanosuspension: a patent overview.
Jethara SI; Patel AD; Patel MR; Patel MS; Patel KR
Recent Pat Drug Deliv Formul; 2015; 9(1):65-78. PubMed ID: 25354346
[TBL] [Abstract][Full Text] [Related]
20. [Research progress on
Shen BD; Shen CY; Xu LX; Zhu WF; Yuan HL
Zhongguo Zhong Yao Za Zhi; 2018 Oct; 43(19):3828-3833. PubMed ID: 30453705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]